Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
28 Jan 2021
Historique:
received: 24 07 2020
accepted: 16 01 2021
entrez: 29 1 2021
pubmed: 30 1 2021
medline: 9 2 2021
Statut: epublish

Résumé

A lack of consensus on the optimal outcome measures to assess the efficacy and effectiveness of interventions for the treatment of opioid use disorder (OUD) has hampered the pooling of research data for evidence synthesis and clinical guidelines. A core outcome set (COS) is a minimum set of outcome measures that are recommended for all studies of a particular condition. The National Drug Abuse Treatment Clinical Trials Network (CTN) Core Outcome Set for OUD (COS-OUD) is a development study to identify core constructs, meaningful outcomes, and their optimal measurement for all efficacy and effectiveness studies of OUD treatment and service delivery. Overseen by an expert workgroup, a modified, stepwise, e-Delphi methodology will be used to gain consensus among a panel of clinical practitioners and researchers involved in the treatment of OUD, who are members of the CTN. Sequential rounds of anonymous, online questionnaires will be used to identify, rate the importance of, and refine a core outcome set. A consensus threshold will be achieved if at least 70% of the panel rate the measure as critical for inclusion in the COS-OUD. Where consensus is not reached or there are suggestions for new measures, these will be brought forward to a further round of review prior to a consensus meeting. Products from this study will be communicated via peer-reviewed scientific journals and conferences. This initiative will develop a COS for OUD intervention trials, treatment studies, and service delivery and will support the pooling of research and clinical practice data and efforts to develop measurement-based care within the OUD treatment cascade. http://www.comet-initiative.org/Studies/Details/1579.

Sections du résumé

BACKGROUND BACKGROUND
A lack of consensus on the optimal outcome measures to assess the efficacy and effectiveness of interventions for the treatment of opioid use disorder (OUD) has hampered the pooling of research data for evidence synthesis and clinical guidelines. A core outcome set (COS) is a minimum set of outcome measures that are recommended for all studies of a particular condition. The National Drug Abuse Treatment Clinical Trials Network (CTN) Core Outcome Set for OUD (COS-OUD) is a development study to identify core constructs, meaningful outcomes, and their optimal measurement for all efficacy and effectiveness studies of OUD treatment and service delivery.
METHODS/DESIGN METHODS
Overseen by an expert workgroup, a modified, stepwise, e-Delphi methodology will be used to gain consensus among a panel of clinical practitioners and researchers involved in the treatment of OUD, who are members of the CTN. Sequential rounds of anonymous, online questionnaires will be used to identify, rate the importance of, and refine a core outcome set. A consensus threshold will be achieved if at least 70% of the panel rate the measure as critical for inclusion in the COS-OUD. Where consensus is not reached or there are suggestions for new measures, these will be brought forward to a further round of review prior to a consensus meeting. Products from this study will be communicated via peer-reviewed scientific journals and conferences.
DISCUSSION CONCLUSIONS
This initiative will develop a COS for OUD intervention trials, treatment studies, and service delivery and will support the pooling of research and clinical practice data and efforts to develop measurement-based care within the OUD treatment cascade.
TRIAL REGISTRATION BACKGROUND
http://www.comet-initiative.org/Studies/Details/1579.

Identifiants

pubmed: 33509278
doi: 10.1186/s13063-021-05051-9
pii: 10.1186/s13063-021-05051-9
pmc: PMC7841754
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA046721
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA013034
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1-DA049467
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA013714
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA041071
Pays : United States
Organisme : NCIPC CDC HHS
ID : R01 CE002999
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA049435
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA045632
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA049467
Pays : United States

Références

Trials. 2012 Aug 06;13:132
pubmed: 22867278
PLoS Med. 2017 Nov 16;14(11):e1002447
pubmed: 29145404
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
Lancet. 2019 Apr 27;393(10182):1760-1772
pubmed: 30878228
Trials. 2016 Sep 13;17(1):449
pubmed: 27618914
Subst Abuse Rehabil. 2012 Jul 17;3(1):81-89
pubmed: 22904649
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
BMJ Open. 2018 Dec 4;8(12):e025059
pubmed: 30518592
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Int J Drug Policy. 2019 Sep;71:183-188
pubmed: 30718120
J Health Care Poor Underserved. 2014 Feb;25(1 Suppl):36-45
pubmed: 24583486
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
NCHS Data Brief. 2017 Feb;(273):1-8
pubmed: 28256996
Clin Trials. 2013;10(6):977-86
pubmed: 24085772
Addiction. 2019 Aug;114(8):1346-1353
pubmed: 30614096
BMJ Open. 2018 Oct 18;8(10):e023902
pubmed: 30341139
Clin Trials. 2018 Aug;15(4):413-423
pubmed: 29676586
Neuropsychopharmacology. 2010 Jan;35(1):217-38
pubmed: 19710631
BMJ Open. 2014 Dec 30;4(12):e006682
pubmed: 25550297
J Adv Nurs. 2006 Jan;53(2):205-12
pubmed: 16422719
Front Psychiatry. 2015 Mar 03;6:33
pubmed: 25784882
Addiction. 2013 Jan;108(1):3-8
pubmed: 22563741
Sci Transl Med. 2012 Feb 1;4(119):119mr3
pubmed: 22301552
Trials. 2019 Feb 11;20(1):116
pubmed: 30744706

Auteurs

Niranjan S Karnik (NS)

Department of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 West Jackson Blvd., Suite 600, Chicago, IL, 60612, USA. Niranjan_Karnik@rush.edu.

Cynthia I Campbell (CI)

Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.

Megan E Curtis (ME)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA, 90025, USA.

David A Fiellin (DA)

Yale School of Medicine, Internal Medicine, Program in Addiction Medicine, PO Box 208056, 333 Cedar Street, New Haven, CT, 06520-8056, USA.

Udi Ghitza (U)

National Institute on Drug Abuse, National Institutes of Health, National Institute on Drug Abuse Center for Clinical Trials Network, 6001 Executive Blvd, Bethesda, MD, 20892, USA.

Kathryn Hefner (K)

Yale School of Medicine, Internal Medicine, Program in Addiction Medicine, PO Box 208056, 333 Cedar Street, New Haven, CT, 06520-8056, USA.
The Emmes Company, LLC, National Institute on Drug Abuse Data and Statistics Center and Clinical Coordinating Center, 401 N Washington St, Rockville, MD, 20850, USA.

Yih-Ing Hser (YI)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA, 90025, USA.

R Kathryn McHugh (RK)

Division of Alcohol, Drugs and Addiction, McLean Hospital, & Department of Psychiatry, Harvard Medical School, McLean Hospital, Proctor House 3, 115 Mill St, Belmont, MA, 02478, USA.

Sean M Murphy (SM)

Department of Population Health Sciences, Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10065, USA.

Sterling M McPherson (SM)

Washington State University Elson S. Floyd College of Medicine, 412 E. Spokane Falls Blvd., Spokane, WA, 99202-2131, USA.

Landhing Moran (L)

National Institute on Drug Abuse, National Institutes of Health, National Institute on Drug Abuse Center for Clinical Trials Network, 6001 Executive Blvd, Bethesda, MD, 20892, USA.

Larissa J Mooney (LJ)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA, 90025, USA.

Li-Tzy Wu (LT)

Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3903, Durham, NC, 27710, USA.

Dikla Shmueli-Blumberg (D)

The Emmes Company, LLC, National Institute on Drug Abuse Data and Statistics Center and Clinical Coordinating Center, 401 N Washington St, Rockville, MD, 20850, USA.

Matisyahu Shulman (M)

Department of Psychiatry, Columbia University Irving Medical Center & Department of Psychiatry, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY, USA.

Robert P Schwartz (RP)

Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD, 21201-5633, USA.

Kari A Stephens (KA)

Departments of Family Medicine, Biomedical Informatics & Medical Education, University of Washington, Seattle, WA, 98195, USA.

Katherine E Watkins (KE)

RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401-3208, USA.

John Marsden (J)

Addictions Department, Division of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, DeCrespigny Park, Denmark Hill, London, SE5 8AF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH